High plasma concentrations of lipoprotein(a) [Lp(a), which is encoded by the APOA gene] increase an individual’s risk of developing diseases, such as coronary artery diseases, restenosis, and stroke. Unfortunately, increased Lp(a) levels are minimally influenced by dietary changes or drug treatment. Further, the development of Lp(a)-specific medications has been hampered by limited knowledge of Lp(a) metabolism. In this study, we identified patients suffering from biliary obstructions with very low plasma Lp(a) concentrations that rise substantially after surgical intervention. Consistent with this, common bile duct ligation in mice transgenic for human APOA (tg-APOA mice) lowered plasma concentrations and hepatic expression of APOA. To test whether farnesoid X receptor (FXR), which is activated by bile acids, was responsible for the low plasma Lp(a) levels in cholestatic patients and mice, we treated tg-APOA and tg-APOA/Fxr–/– mice with cholic acid. FXR activation markedly reduced plasma concentrations and hepatic expression of human APOA in tg-APOA mice but not in tg-APOA/Fxr–/– mice. Incubation of primary hepatocytes from tg-APOA mice with bile acids dose dependently downregulated APOA expression. Further analysis determined that the direct repeat 1 element between nucleotides –826 and –814 of the APOA promoter functioned as a negative FXR response element. This motif is also bound by hepatocyte nuclear factor 4α (HNF4α), which promotes APOA transcription, and FXR was shown to compete with HNF4α for binding to this motif. These findings may have important implications in the development of Lp(a)-lowering medications.
Indumathi Chennamsetty, Thierry Claudel, Karam M. Kostner, Anna Baghdasaryan, Dagmar Kratky, Sanja Levak-Frank, Sasa Frank, Frank J. Gonzalez, Michael Trauner, Gert M. Kostner
Title and authors | Publication | Year |
---|---|---|
Comparative Analysis of Atherogenic Lipoproteins L5 and Lp(a) in Atherosclerotic Cardiovascular Disease.
Akyol O, Yang CY, Woodside DG, Chiang HH, Chen CH, Gotto AM |
Current Atherosclerosis Reports | 2024 |
Lipoprotein(a) and cardiovascular disease.
Boffa MB, Koschinsky ML |
The Biochemical journal | 2024 |
Calcific aortic valve disease: mechanisms, prevention and treatment.
Moncla LM, Briend M, Bossé Y, Mathieu P |
Nature reviews. Cardiology | 2023 |
Transcriptional Control of Trpm6 by the Nuclear Receptor FXR
E Kim, J Lee |
International journal of molecular sciences | 2022 |
Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus
Kostner KM, Kostner GM |
International journal of molecular sciences | 2022 |
Genome-Wide Characterization of a Highly Penetrant Form of Hyperlipoprotein(a)emia Associated With Genetically Elevated Cardiovascular Risk.
Coassin S, Chemello K, Khantalin I, Forer L, Döttelmayer P, Schönherr S, Grüneis R, Chong-Hong-Fong C, Nativel B, Ramin-Mangata S, Gallo A, Roche M, Muelegger B, Gieger C, Peters A, Zschocke J, Marimoutou C, Meilhac O, Lamina C, Kronenberg F, Blanchard V, Lambert G |
Circulation. Genomic and precision medicine | 2022 |
Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care
Loh WJ, Chan DC, Mata P, Watts GF |
Frontiers in Genetics | 2022 |
Study on the relationship between hormone and Lp(a) in Chinese overweight/obese patients
Chang X, Bian N, Ding X, Li J, An Y, Wang J, Liu J, Wang G |
BMC Endocrine Disorders | 2022 |
Dietary supplementation of porcine bile acids improves laying performance, serum lipid metabolism and cecal microbiota in late-phase laying hens.
Yang B, Huang S, Zhao G, Ma Q |
2022 | |
Metabolic Effect of Blocking Sodium-Taurocholate Co-Transporting Polypeptide in Hypercholesterolemic Humans with a Twelve-Week Course of Bulevirtide-An Exploratory Phase I Clinical Trial.
Stoll F, Seidel-Glätzer A, Burghaus I, Göring O, Sauter M, Rose P, Daniel V, Haag M, Schwab M, Riffel J, André F, Taylor L, Weiss J, Burhenne J, Cleeves V, Haefeli WE, Blank A |
International journal of molecular sciences | 2022 |
Liver macrophages and inflammation in physiology and physiopathology of non‐alcoholic fatty liver disease
R Thibaut, MC Gage, I PinedaTorra, G Chabrier, N Venteclef, F Alzaid |
The FEBS journal | 2021 |
Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation
G Reyes-Soffer, M Westerterp |
Pharmacological research : the official journal of the Italian Pharmacological Society | 2021 |
Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease
Y Xiao, M Kim, MA Lazar |
Molecular Metabolism | 2020 |
A genome-wide analysis of DNA methylation identifies a novel association signal for Lp(a) concentrations in the LPA promoter
S Coassin, N Hermann-Kleiter, M Haun, S Wahl, R Wilson, B Paulweber, S Kunze, T Meitinger, K Strauch, A Peters, M Waldenberger, F Kronenberg, C Lamina, DC Crawford |
PloS one | 2020 |
Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
MF Greco, CR Sirtori, A Corsini, M Ezhov, T Sampietro, M Ruscica |
Journal of Clinical Medicine | 2020 |
Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?
NC Ward, KM Kostner, DR Sullivan, P Nestel, GF Watts |
Journal of Clinical Medicine | 2019 |
Lipoprotein(a) Change After Sleeve Gastrectomy Is Affected by the Presence of Metabolic Syndrome
S Paredes, M Alves, ML Pereira, O Marques, L Ribeiro |
Obesity Surgery | 2019 |
Changes in lipoprotein(a) following bariatric surgery
BX Lin, MC Weiss, M Parikh, JS Berger, EA Fisher, SP Heffron |
American Heart Journal | 2018 |
Lipoprotein(a) Mass Levels Increase Significantly According to APOE GenotypeHighlights: An Analysis of 431 239 Patients
PM Moriarty, SA Varvel, PL Gordts, JP McConnell, S Tsimikas |
Arteriosclerosis, thrombosis, and vascular biology | 2017 |
Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials
A Sahebkar, LE Simental-Mendía, GF Watts, MC Serban, M Banach |
BMC Medicine | 2017 |
Effect of diet-induced weight loss on lipoprotein(a) levels in obese individuals with and without type 2 diabetes
KA Berk, R Yahya, AJ Verhoeven, J Touw, FP Leijten, EF van Rossum, VL Wester, MA Lips, H Pijl, R Timman, G Erhart, F Kronenberg, JE van Lennep, EJ Sijbrands, MT Mulder |
Diabetologia | 2017 |
Diallyl disulphide inhibits apolipoprotein(a) expression in HepG2 cells through the MEK1-ERK1/2-ELK-1 pathway
X Ma, Y Liu, Y Tan, K Qu, X He, H Zhang, Z Wang |
Lipids in Health and Disease | 2017 |
Nat1 Deficiency Is Associated with Mitochondrial Dysfunction and Exercise Intolerance in Mice
I Chennamsetty, M Coronado, K Contrepois, MP Keller, I Carcamo-Orive, J Sandin, G Fajardo, AJ Whittle, M Fathzadeh, M Snyder, G Reaven, AD Attie, D Bernstein, T Quertermous, JW Knowles |
Cell Reports | 2016 |
Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases
F Kronenberg |
Cardiovascular Drugs and Therapy | 2016 |
Transcriptional coordination of hepatic autophagy by nutrient-sensing nuclear receptor PPARα and FXR
JM Lee |
Annals of Pediatric Endocrinology & Metabolism | 2016 |
Lipoprotein (a): a historical appraisal
KM Kostner, GM Kostner |
Journal of lipid research | 2016 |
Identification and validation of NAT2 as an insulin sensitivity gene
Joshua Knowles, Weijia Xie, Zhongyang Zhang, Indumathi Chennemsetty, Themistocles Assimes, Jussi Paananen, Ola Hansson, James Pankow, Mark Goodarzi, Ivan Carcamo-Orive, Andrew Morris, Yii-Der I. Chen, Ville-Petteri Makinen, Andrea Ganna, Xiuqing Guo, Anubha Mahajan, Fahim Abbasi, Danielle Greenawalt, Pek Lum, Cliona Molony, Lars Lind, Cecilia Lindgren, Leslie Raffel, Philip S. Tsao, Eric Schadt, Jerome I. Rotter, Alan Sinaiko, Gerald M. Reaven, Xia Yang, Chao A. Hsiung, Leif Groop, Heather Cordell, Markku Laakso, Ke Hao, Erik Ingelsson, Timothy Frayling, Michael Weedon, Mark Walker, Thomas Quertermous |
Journal of Clinical Investigation | 2015 |
Metabolic Control
S Herzig |
2015 | |
Targeting Lipoprotein (a): an Evolving Therapeutic Landscape
LC Man, E Kelly, D Duffy |
Current Atherosclerosis Reports | 2015 |
Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population
L Ding, A Song, M Dai, M Xu, W Sun, B Xu, J Sun, T Wang, Y Xu, J Lu, W Wang, Y Bi, G Ning |
Journal of lipid research | 2015 |
Nuclear bile acid signaling through the farnesoid X receptor
C Mazuy, A Helleboid, B Staels, P Lefebvre |
Cellular and Molecular Life Sciences | 2014 |
Nutrient-sensing nuclear receptors coordinate autophagy
JM Lee, M Wagner, R Xiao, KH Kim, D Feng, MA Lazar, DD Moore |
Nature | 2014 |
FGF21 inhibits apolipoprotein(a) expression in HepG2 cells via the FGFR1-ERK1/2-Elk-1 pathway
X Lin, G Li, X He, X Ma, K Zhang, H Zhang, G Zeng, Z Wang |
Molecular and Cellular Biochemistry | 2014 |
Relook at lipoprotein (A): independent risk factor of coronary artery disease in north Indian population
J Yusuf, N Yadav, S Mukhopadhyay, A Goyal, V Mehta, V Trehan, S Tyagi |
Indian Heart Journal | 2014 |
Update on Lipoprotein(a) as a Cardiovascular Risk Factor and Mediator
MB Boffa, ML Koschinsky |
Current Atherosclerosis Reports | 2013 |
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
G Porez, J Prawitt, B Gross, B Staels |
Journal of lipid research | 2012 |
Lipoprotein(a) metabolism: Potential sites for therapeutic targets
J Hoover-Plow, M Huang |
Metabolism | 2012 |
Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice
I Chennamsetty, KM Kostner, T Claudel, M Vinod, S Frank, TS Weiss, M Trauner, GM Kostner |
Journal of lipid research | 2012 |
A Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and Atherosclerosis
I Missala, U Kassner, E Steinhagen-Thiessen |
International Journal of Rheumatology | 2012 |